Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Davies, Faith E  [Clear All Filters]
2023
Jones JR, Cairns DA, Menzies T, Pawlyn C, Davies FE, Sigsworth R, Brioli A, Jenner MW, Kaiser MF, Olivier C, et al. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. EClinicalMedicine. 2023;62:102099.
2022
de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, Jones JR, Hockaday A, Henderson R, Cook G, et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. J Clin Oncol. 2022:JCO2102228.
Thompson MA, Boccadoro M, Leleu X, Vela-Ojeda J, Van Rhee F, Weisel KC, Rifkin RM, Usmani SZ, Hajek R, Cook G, et al. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2022.
2019
Cook G, Royle K-L, Pawlyn C, Hockaday A, Shah V, Kaiser MF, Brown SR, Gregory WM, J Child A, Davies FE, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019.
2018
Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, Van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, et al. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol. 2018.
2013
Rawstron AC, J Child A, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, et al. Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013.